Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Inclusion Criteria: * Completion of either of the JIGSAW studies, study WA28117 (for participants with pJIA) or study WA28118 (for participants with sJIA) * Adequate disease control with the use of SC tocilizumab(TCZ)(comparable to the use of IV TCZ, if received prior to enrollment in the JIGSAW study), per clinical judgment of the investigator * For participants of reproductive potential: agreement to remain abstinent or use of effective contraception as defined by the study protocol Exclusion Criteria: * Prior discontinuation of SC tocilizumab because of inadequate clinical response during participation in a JIGSAW study * Poorly controlled disease (in opinion of treating physician) despite treatment with SC tocilizumab in the JIGSAW study * Prior discontinuation of intravenous tocilizumab because of inadequate clinical response or safety events (including hypersensitivity) * Therapy with biologic agents (except tocilizumab) in the period between completion of the JIGSAW study and screening for the current study * Concurrent treatment with disease-modifying anti-rheumatic drugs (DMARDs) (including methotrexate), nonsteroidal anti-inflammatory drugs (NSAIDs), and oral corticosteroids is permitted at the discretion of the investigator * Use of live or attenuated vaccines and immunosuppressants, such as cyclosporine and cyclophosphamide * Any significant concurrent medical or surgical conditions or findings that would jeopardize the participant's safety or ability to comple…